Beam Therapeutics Inc.

NASDAQ:BEAM

Biotechnology

Healthcare
$21.01 +1.46%

+$0.48 today

Market cap
$2.17B
Beta
2.20
P/E (TTM)
-52.3
EPS (TTM)
-$0.63
52W Low $15.60High $36.44

Volume 4.86M

Average 2.11M

BEAM Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Beam Therapeutics Inc.NASDAQ: BEAM

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 100.0%

Gross margin was 100.0% in Q2 FY2026, up 0.0 pp from a year earlier. On a trailing-twelve-month basis it was 100.0%, up 0.0 pp year over year. Over 3 fiscal years it widened by 495.5 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
100.0%+0.0 pp QoQ
Last fiscal yearDec 2025
84.0%+562.7 pp YoY
LTMJun 2026
100.0%+0.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.0 pp——
1 year+562.7 pp——
3 years+495.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
84.0%
Year-over-year change
+562.7pp

Gross Margin vs competitors

How BEAM compares with its peers on the latest reported figures

  • BEAM's LTM Jun 2026 gross margin of 100.0% is the highest of the 8 companies compared; the peer median is 5.8%.
  • Its year-over-year change of +0.0 pp is the 6th highest of 8, against a peer median of +124.1 pp.
  • Over three fiscal years its change of +495.5 pp compares with a peer median of -6.4 pp.
BEAM Competitors Peer median
Gross Margin for BEAM and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026100.0% +0.0 pp+495.5 pp
DTILPrecision BioSciences, Inc.LTM Mar 202697.0% -3.0 pp-8.0 pp
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
CLLSCellectis S.A.LTM Mar 202681.9% +0.5 pp+30.8 pp
EDITEditas Medicine, Inc.LTM Mar 20265.8% +124.1 pp+32.1 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-153.7% +248.0 pp-9.0 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
CRSPCRISPR Therapeutics AGLTM Sep 2026-558.9% -202.1 pp+18649.7 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding BEAM) 5.8%+124.1 pp-6.4 pp

Competitors are the stored peer set for BEAM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue51.84M60.92M377.71M63.52M139.74M
Cost of Revenue232.13M311.59M0367.56M22.29M
Gross Profit(180.29M)(250.67M)377.71M(304.04M)117.45M
Gross Margin-347.8%-411.5%100.0%-478.7%84.0%
Research & Development387.09M311.59M437.38M367.56M409.62M
Selling, General & Admin57.22M87.81M116.81M111.53M113.82M
Operating Expenses212.18M87.81M554.19M111.53M501.14M
Depreciation & Amortization7.45M14.15M20.01M21.93M22.29M
EBITDA(230.06M)(271.53M)(111.15M)(354.78M)(13.97M)
EBITDA Margin-443.8%-445.7%-29.4%-558.5%-10.0%
Operating Income(392.47M)(338.48M)(176.49M)(415.57M)(383.69M)
Operating Margin-757.0%-555.6%-46.7%-654.3%-274.6%
Interest Income015.3M46.68M49.09M0
Interest Expense000043.73M
Other Income / Expenses21.83M52.8M45.32M38.87M303.7M
Income Before Tax(370.64M)(285.68M)(131.16M)(376.7M)(79.99M)
Pre-Tax Margin-714.9%-468.9%-34.7%-593.1%-57.2%
Income Tax Expense03.41M1.37M39K0
Net Income(370.64M)(289.09M)(132.53M)(376.74M)(79.99M)
Net Margin-714.9%-474.5%-35.1%-593.1%-57.2%
EPS (Basic)(5.77)(4.13)(1.72)(4.58)(0.81)
EPS (Diluted)(5.77)(4.13)(1.72)(4.58)(0.81)
Weighted Avg Shares64.23M70.02M77.15M82.31M98.91M
Weighted Avg Shares (Diluted)64.23M70.02M77.15M82.31M98.91M

Beam Therapeutics Inc.

NASDAQ:BEAM

Intrinsic Alpha fair value

Locked

Current Price

$21.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.